Ann: Bisantrene shows potent anticancer activity in AML models, page-57

It doesn’t appear that FTO is involved in the synergy between bisantrene and decitabine - at least based on the data presented in the poster. Bisantrene is a very interesting drug and not everything is about FTO.

To answer your other questions.

1. Mouse models of leukaemia are closer to human disease than solid tumours, but there are lots of variables - this is why we do human trials.

2. It is hard to directly translate dose from mice to humans, but around 50-80/m2 would be a good rough estimate. This is pretty low by human standards. Of course like everything, mice are not little humans so we are going to have to wait until we see human data on the combination to know how well it will work. Things do look about as good as you could hope for from an animal model.